Opendata, web and dolomites

PULTAR

Delivery of PULmonary Therapeutics through TARgetted Delivery using Phononics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PULTAR project word cloud

Explore the words cloud of the PULTAR project. It provides you a very rough idea of what is the project "PULTAR" about.

commercial    therapies    disease    50m    forms    closely    people    extremely    asthma    pulmonary    lung    enhanced    235    ultrasonic    clinical    hypertension    nebulisation    gene    shown    barriers    according    medicine    medicines    worldwide    3m    sizes    types    genes    mu    cystic    droplet    healthcare    team    gt    treating    aerosols    outcomes    obstructive    regions    treatment    nebuliser    innovation    market    monodisperse    delivered    strand    industry    aerosol    64m    again    therapeutic    improves    chronic    create    selective    inhalation    appealing    data    fibrosis    substantial    wisdom    million    therapy    arterial    deaths    tissue    transits    anatomical    model    proprietary    mouse    respiratory    vascular    suffer    epithelium    rna    quality    prototype    cells    lungs    similarly    droplets    biologics    amount    diseases    patients    precise    drug    start    difficult    routes    efficacy    reduce    380b    accepted    generally    limitations    dalys   

Project "PULTAR" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF GLASGOW 

Organization address
address: UNIVERSITY AVENUE
city: GLASGOW
postcode: G12 8QQ
website: www.gla.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙791 €
 EC max contribution 149˙791 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF GLASGOW UK (GLASGOW) coordinator 149˙791.00

Map

 Project objective

According to the WHO 235 million people suffer from asthma and 64M people have chronic obstructive pulmonary disease, leading to 3M deaths per year worldwide. The cost of treating patients with all forms of lung disease is ~ €380B p.a., leading to the loss of >50M DALYS. Generally, patients with such respiratory diseases are treated by inhalation of medicines within aerosols, where the therapy (including medicine or biologics used in gene therapy) can be targeted directly to the lung. The accepted wisdom is that such pulmonary delivery requires aerosol droplet sizes of between 1 and 5 μm. We have now shown that by using a new ultrasonic technology, we can create monodisperse aerosol droplets, which could be used for therapeutic delivery of medicines, genes and RNA to specific regions in the lungs. In one strand of the work we aim to demonstrate that this precise nebulisation technology improves the efficacy of treatment through enhanced drug uptake. In a second strand, we will demonstrate selective targeting of different tissue types in the lungs. For example, the epithelium in cystic fibrosis patients is currently extremely difficult to access leading to limitations in the amount and quality of data obtained for pre-clinical and clinical gene therapies. Similarly, targeting vascular cells is an appealing treatment for patients with pulmonary arterial hypertension, although, again, effective delivery necessitates that the therapeutic system transits defined and substantial anatomical barriers. The overall aim is to demonstrate that this new technology can define routes to new therapies, improve clinical outcomes and reduce healthcare costs. To achieve this we will develop a prototype nebuliser based upon proprietary technology and show that different medicines and gene therapies can be delivered effectively to the lungs of a model mouse. We will also start to build a commercial team and work closely with industry to deliver impact and innovation to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PULTAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PULTAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

RESOURCE Q (2019)

Efficient Conversion of Quantum Information Resources

Read More